JW (CAYMAN) THERAPEUTICS CO. LTD Financials JW (Cayman) Therapeutics Co. Ltd
Equities
2126
KYG5210T1040
Biotechnology & Medical Research
|
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
| 1.83 HKD | +0.55% |
|
+4.57% | -19.03% |
| Mar. 20 | JW (Cayman) Therapeutics Shrinks Loss in Fiscal 2023 | MT |
| Mar. 20 | JW Therapeutics Co. Ltd Reports Earnings Results for the Full Year Ended December 31, 2023 | CI |
Valuation
| Fiscal Period: December | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|
| Capitalization 1 | 8,603 | 4,345 | 1,538 | 679.3 | 679.3 | - |
| Enterprise Value (EV) 1 | 6,085 | 2,658 | 433.3 | 137.7 | 366 | 789.9 |
| P/E ratio | -1.76 x | -6.22 x | -1.86 x | -1.1 x | -1.16 x | -1.34 x |
| Yield | - | - | - | - | - | - |
| Capitalization / Revenue | - | 141 x | 10.6 x | 4.74 x | 2.53 x | 1.63 x |
| EV / Revenue | - | 86.3 x | 2.97 x | 0.79 x | 1.36 x | 1.89 x |
| EV / EBITDA | -14.6 x | -3.6 x | -0.68 x | -0.29 x | -0.7 x | -1.87 x |
| EV / FCF | -15.6 x | -3.81 x | -0.66 x | -0.31 x | -0.59 x | -1.77 x |
| FCF Yield | -6.43% | -26.3% | -153% | -319% | -169% | -56.5% |
| Price to Book | - | 1.57 x | 0.67 x | 0.5 x | 0.66 x | 1.34 x |
| Nbr of stocks (in thousands) | 387,906 | 396,795 | 400,201 | 403,525 | 403,525 | - |
| Reference price 2 | 22.18 | 10.95 | 3.842 | 1.683 | 1.683 | 1.683 |
| Announcement Date | 3/26/21 | 3/23/22 | 3/29/23 | 3/20/24 | - | - |
1CNY in Million2CNY
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|
| Net sales 1 | - | - | 30.8 | 145.7 | 173.9 | 268.1 | 417.8 |
| EBITDA 1 | - | -417.2 | -737.5 | -634.9 | -481 | -523.6 | -421.7 |
| EBIT 1 | - | -440.8 | -777.6 | -719.7 | -578.6 | -584.8 | -487.8 |
| Operating Margin | - | - | -2,524.93% | -493.95% | -332.83% | -218.09% | -116.78% |
| Earnings before Tax (EBT) 1 | - | -1,664 | -702.3 | -846.1 | -768 | -596.7 | -513.6 |
| Net income 1 | -633.3 | -1,664 | -702.3 | -846.1 | -768 | -596.6 | -513.5 |
| Net margin | - | - | -2,280.51% | -580.73% | -441.74% | -222.52% | -122.91% |
| EPS 2 | -9.740 | -12.61 | -1.760 | -2.060 | -1.870 | -1.457 | -1.253 |
| Free Cash Flow 1 | - | -391.2 | -698.3 | -660.8 | -620.8 | -619.5 | -446.5 |
| FCF margin | - | - | -2,267.52% | -453.53% | -316.24% | -231.05% | -106.88% |
| FCF Conversion (EBITDA) | - | - | - | - | - | - | - |
| FCF Conversion (Net income) | - | - | - | - | - | - | - |
| Dividend per Share | - | - | - | - | - | - | - |
| Announcement Date | 10/21/20 | 3/26/21 | 3/23/22 | 3/29/23 | 3/20/24 | - | - |
1CNY in Million2CNY
Estimates
Income Statement Evolution (Quarterly data)
| Fiscal Period: December | 2020 S2 | 2021 S1 | 2021 S2 | 2022 S1 | 2022 S2 | 2023 S1 | 2023 S2 | 2024 S1 | 2024 S2 |
|---|---|---|---|---|---|---|---|---|---|
| Net sales 1 | - | - | 30.8 | 66.01 | 79.7 | 87.74 | 86.12 | 107.7 | 131.7 |
| EBITDA | - | - | - | - | - | - | - | - | - |
| EBIT 1 | - | -336.8 | -440.8 | -348.1 | -371.6 | -310.6 | -268.1 | -273.4 | -279.9 |
| Operating Margin | - | - | -1,431.36% | -527.41% | -466.25% | -353.98% | -311.28% | -253.82% | -212.57% |
| Earnings before Tax (EBT) | - | - | - | - | - | - | - | - | - |
| Net income | - | - | - | - | - | - | - | - | - |
| Net margin | - | - | - | - | - | - | - | - | - |
| EPS 2 | - | -0.7100 | -1.050 | -1.050 | -1.010 | -0.9300 | -0.9400 | -0.6400 | -0.6600 |
| Dividend per Share | - | - | - | - | - | - | - | - | - |
| Announcement Date | 3/26/21 | 8/27/21 | 3/23/22 | 8/30/22 | 3/29/23 | 8/29/23 | 3/20/24 | - | - |
1CNY in Million2CNY
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|
| Net Debt 1 | - | - | - | - | - | - | 111 |
| Net Cash position 1 | - | 2,518 | 1,687 | 1,104 | 687 | 313 | - |
| Leverage (Debt/EBITDA) | - | - | - | - | - | - | -0.2623 x |
| Free Cash Flow 1 | - | -391 | -698 | -661 | -621 | -620 | -447 |
| ROE (net income / shareholders' equity) | - | -134% | -22.6% | -32.9% | -38% | -46.1% | -71% |
| ROA (Net income/ Total Assets) | - | -74.8% | -20.4% | -28.6% | -31.1% | -29.3% | -25.5% |
| Assets 1 | - | 2,224 | 3,448 | 2,954 | 2,469 | 2,036 | 2,018 |
| Book Value Per Share 2 | - | - | 6.980 | 5.740 | 4.090 | 2.550 | 1.260 |
| Cash Flow per Share 2 | - | -1.980 | -1.400 | -1.310 | -1.440 | -1.340 | -1.060 |
| Capex | - | 130 | 137 | 124 | - | 80 | 80 |
| Capex / Sales | - | - | 445.27% | 85.16% | - | 29.84% | 19.15% |
| Announcement Date | 10/21/20 | 3/26/21 | 3/23/22 | 3/29/23 | 3/20/24 | - | - |
1CNY in Million2CNY
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
Trading Rating
Investor Rating
ESG Refinitiv
Sell
Buy
Mean consensus
BUY
Number of Analysts
3
Last Close Price
1.683
CNY
Average target price
2.508
CNY
Spread / Average Target
+48.98%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -19.03% | 93.83M | |
| -2.63% | 102B | |
| +1.62% | 96.29B | |
| +1.46% | 22.18B | |
| -16.67% | 21.2B | |
| -8.58% | 18.31B | |
| -38.74% | 17.38B | |
| -13.21% | 16.36B | |
| +5.41% | 13.97B | |
| +33.57% | 12.17B |
- Stock Market
- Equities
- 2126 Stock
- Financials JW (Cayman) Therapeutics Co. Ltd
